25.56
1.79 (7.53%)
| Penutupan Terdahulu | 23.77 |
| Buka | 23.64 |
| Jumlah Dagangan | 272,472 |
| Purata Dagangan (3B) | 312,085 |
| Modal Pasaran | 1,144,428,288 |
| Harga / Pendapatan (P/E Ke hadapan) | 106.38 |
| Harga / Jualan (P/S) | 53.76 |
| Harga / Buku (P/B) | 3.06 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Nov 2025 |
| Margin Operasi (TTM) | -11,831.05% |
| EPS Cair (TTM) | -1.78 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -30.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 6.25% |
| Nisbah Semasa (MRQ) | 32.19 |
| Aliran Tunai Operasi (OCF TTM) | -74.10 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -25.69 M |
| Pulangan Atas Aset (ROA TTM) | -17.20% |
| Pulangan Atas Ekuiti (ROE TTM) | -30.96% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Septerna, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 1.00 |
|
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 2.64% |
| % Dimiliki oleh Institusi | 105.46% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 30.00 (HC Wainwright & Co., 17.37%) | Beli |
| Median | 29.00 (13.46%) | |
| Rendah | 28.00 (Wells Fargo, 9.55%) | Beli |
| Purata | 29.00 (13.46%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 21.25 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wells Fargo | 14 Nov 2025 | 28.00 (9.55%) | Beli | 23.27 |
| HC Wainwright & Co. | 11 Nov 2025 | 30.00 (17.37%) | Beli | 19.24 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 25 Nov 2025 | Pengumuman | Septerna to Participate in 8th Annual Evercore Healthcare Conference |
| 10 Nov 2025 | Pengumuman | Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results |
| 03 Nov 2025 | Pengumuman | Septerna to Participate in Upcoming Investor Conferences |
| 29 Sep 2025 | Pengumuman | Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |